ALBERTDAVDNSEAlbert David Limited· Pharmaceuticals & BiotechnologyCriticalNegative

Announced Thu, 18 Dec, 2025 · 19:33 IST

Albert David MD and CEO Umesh Mr. Kunte resigns citing personal reasons

Ceo ResignedManagement Changes View source PDF Explain this filing

ALBERTDAVD · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.1%Reaction day

₹744.20

prior close

₹747.20

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.3%-1.4% vs market

Pharmaceuticals peers, median of 153sector+0.7%-0.9% vs sector

On the reaction day the stock moved 1.4 pts less than Nifty Microcap 250 and 0.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.0

15m

+0.0

30m

-0.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.1+1.3-1.4+0.7-0.9

Next day

+0.9+2.6-1.7+1.3-0.4

+0.8+2.7-1.9+1.4-0.7

+0.8+2.1-1.4+1.4-0.7

+0.9+1.6-0.7+0.7+0.2

-0.6+0.8-1.4+0.0-0.6

-0.7+2.2-2.9+0.7-1.4

15d

+0.4-1.6+2.0-1.1+1.5

-7.3-3.0-4.2-1.8-5.5

-4.0-1.6-2.4-3.9-0.1

-9.8-10.5+0.6-10.2+0.4

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 153Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Mr. Umesh Manohar Kunte has resigned as Managing Director, CEO and Director of Albert David Limited effective close of business hours on December 18, 2025, citing personal reasons and priorities. He will also cease to be a Key Managerial Person under the Companies Act, 2013. The Board accepted the resignation at a meeting held the same day.

Likely market impact

Top leadership vacancy created. Company must appoint a new MD and CEO, which may cause short-term uncertainty for investors.